We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+4.69%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.12B
AUM Growth
–
Cap. Flow
+$1.66B
Cap. Flow
% of AUM
78.16%
Top 10 Holdings %
Top 10 Hldgs %
29.11%
Holding
114
New
97
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$77.5M |
| 2 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$72.9M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$58.5M |
| 4 |
Pfizer
PFE
|
+$54M |
| 5 |
NXTM
NxStage Medical Inc.
NXTM
|
+$49.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.73% |
| 2 | Technology | 1.58% |
| 3 | Financials | 1.05% |
| 4 | Energy | 0.02% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
AbbVie
ABBV
$450B
| $25.5M | 1.2% |
+617,000
| New | +$27M |
|
|
AGN
27
CALL
DELISTED
Allergan Inc
AGN
| $25.3M | 1.19% |
+300,000
| New | +$31.1M |
|
|
STJ
28
DELISTED
St Jude Medical
STJ
| $24M | 1.13% |
+525,000
| New | +$22.8M |
|
|
AET
29
DELISTED
Aetna Inc
AET
| $22.2M | 1.05% |
+350,000
| New | +$20.6M |
|
|
ARIA
30
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $22.1M | 1.04% |
+1,265,104
| New | +$22.4M |
|
31
Alnylam Pharmaceuticals
ALNY
$35.7B
| $21.5M | 1.01% |
+694,000
| New | +$18.5M |
|
|
HTWR
32
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $21.4M | 1.01% |
+225,167
| New | +$20.5M |
|
33
Molina Healthcare
MOH
$11.7B
| $21.2M | 1% |
+570,000
| New | +$20.1M |
|
34
Cytokinetics
CYTK
$10.9B
| $20.6M | 0.97% |
+1,779,622
| New | +$14M |
|
|
CLVS
35
DELISTED
Clovis Oncology, Inc.
CLVS
| $20.5M | 0.97% |
+306,018
| New | +$13.8M |
|
|
XNPT
36
DELISTED
XENOPORT, INC.
XNPT
| $20.1M | 0.95% |
+4,070,090
| New | +$24.7M |
|
37
HCA Healthcare
HCA
$82.3B
| $19.9M | 0.94% |
+553,020
| New | +$21.4M |
|
|
ARNA
38
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $19.8M | 0.93% |
+256,859
| New | +$21M |
|
39
Acadia Pharmaceuticals
ACAD
$4.38B
| $19.4M | 0.91% |
+1,067,115
| New | +$14.7M |
|
40
Tenet Healthcare
THC
$16.8B
| $18.8M | 0.89% |
+408,120
| New | +$18.3M |
|
|
PCYC
41
DELISTED
PHARMACYCLICS INC
PCYC
| $18M | 0.85% |
+227,030
| New | +$18.6M |
|
42
Humana
HUM
$48B
| $15.9M | 0.75% |
+188,000
| New | +$14.8M |
|
43
BioMarin Pharmaceuticals
BMRN
$11.5B
| $13.8M | 0.65% |
+247,000
| New | +$15.4M |
|
44
CALL
Edwards Lifesciences
EW
$49.4B
| $13.4M | 0.63% |
+1,200,000
| New | +$14.2M |
|
|
ACHN
45
DELISTED
Achillion Pharmaceuticals
ACHN
| $13.3M | 0.63% |
+1,629,833
| New | +$12.4M |
|
|
PTLA
46
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $13M | 0.61% |
+527,410
| New | +$10.5M |
|
|
CEMP
47
DELISTED
Cempra, Inc.
CEMP
| $12.5M | 0.59% |
+1,606,510
| New | +$11.1M |
|
48
Pacific Biosciences
PACB
$447M
| $12.4M | 0.58% |
+4,884,368
| New | +$12.2M |
|
|
BDSI
49
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $10.6M | 0.5% |
+2,617,586
| New | +$12.3M |
|
|
DNDN
50
PUT
DELISTED
DENDREON CORPORATION
DNDN
| $10.3M | 0.49% |
+2,500,000
| New | +$10.6M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Deerfield Management, which disclosed 114 positions worth $2.12B. Its ten largest holdings account for 29% of the portfolio.
Its largest position is AUXILIUM PHARAMCEUTICALS INC: 4,850,644 shares worth $80.7M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, followed by Technology and Financials.
- Deerfield Management's largest Q2 2013 buy was AUXILIUM PHARAMCEUTICALS INC: 4,850,644 shares worth $80.7M.
- Deerfield Management's ten largest holdings make up 29% of its $2.12B portfolio in Q2 2013.
- Deerfield Management disclosed 114 positions in Q2 2013, its first 13F filing on record.
Based on Deerfield Management's 13F filing for Q2 2013, filed 14 Aug 2013.